Natera
Natera Ramping up R&D, Commercial Spending as Q1 Product Revenues Rise 37 Percent, Beat Estimates
Premium
The firm trimmed its Q1 net loss and has begun investing heavily in R&D and commercial operations to drive future growth.
Cell-free DNA assays are changing the way transplant surgeons conduct routine surveillance and steroid weaning.
Natera Enrolls First Patients in HEROES Metastatic HER2+ Breast Cancer Trial
Natera's Signatera test and diagnostic imaging will be used to monitor patients for progression-free survival over the course of one year.
Natera Q4, Full-Year Revenues Soar on Product Revenue Gains
Natera processed approximately 792,800 tests in the fourth quarter of 2024 compared to 626,800 tests in Q4 2023.
Natera MRD Test Receives MolDx Coverage for Lung Cancer Surveillance
The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.
Jan 31, 2025
Jan 27, 2025
Jan 15, 2025
Jan 2, 2025
360Dx Top 30 Rebounds in 2024, Rises 4 Percent
Nov 12, 2024
Natera Q3 Revenues Grow 64 Percent
Aug 1, 2024
360Dx Top 30 Jumps 11 Percent in July
Jun 5, 2024